SGLT2 inhibitors: diabetic kidney disease and beyond

Am J Physiol Renal Physiol. 2020 Nov 1;319(5):F780-F781. doi: 10.1152/ajprenal.00518.2020. Epub 2020 Oct 5.
No abstract available

Keywords: Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation trial; Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease trial; kidney in cardiovascular disease; sodium-glucose cotransporter-2; sodium-glucose cotransporter-2 inhibitors.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Comment

MeSH terms

  • American Heart Association
  • Diabetes Mellitus*
  • Diabetic Nephropathies* / drug therapy
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Renal Insufficiency, Chronic*
  • Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2 Inhibitors